Literature DB >> 16396980

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

B Combe1, R Landewe, C Lukas, H D Bolosiu, F Breedveld, M Dougados, P Emery, G Ferraccioli, J M W Hazes, L Klareskog, K Machold, E Martin-Mola, H Nielsen, A Silman, J Smolen, H Yazici.   

Abstract

OBJECTIVE: To formulate EULAR recommendations for the management of early arthritis.
METHODS: In accordance with EULAR's "standardised operating procedures", the task force pursued an evidence based approach and an approach based on expert opinion. A steering group comprised of 14 rheumatologists representing 10 European countries. The group defined the focus of the process, the target population, and formulated an operational definition of "management". Each participant was invited to propose issues of interest regarding the management of early arthritis or early rheumatoid arthritis. Fifteen issues for further research were selected by use of a modified Delphi technique. A systematic literature search was carried out. Evidence was categorised according to usual guidelines. A set of draft recommendations was proposed on the basis of the research questions and the results of the literature search.. The strength of the recommendations was based on the category of evidence and expert opinion.
RESULTS: 15 research questions, covering the entire spectrum of "management of early arthritis", were formulated for further research; and 284 studies were identified and evaluated. Twelve recommendations for the management of early arthritis were selected and presented with short sentences. The selected statements included recognition of arthritis, referral, diagnosis, prognosis, classification, and treatment of early arthritis (information, education, non-pharmacological interventions, pharmacological treatments, and monitoring of the disease process). On the basis of expert opinion, 11 items were identified as being important for future research.
CONCLUSIONS: 12 key recommendations for the management of early arthritis or early rheumatoid arthritis were developed, based on evidence in the literature and expert consensus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16396980      PMCID: PMC1798412          DOI: 10.1136/ard.2005.044354

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  146 in total

1.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Authors:  Lars Klareskog; Désirée van der Heijde; Julien P de Jager; Andrew Gough; Joachim Kalden; Michel Malaise; Emilio Martín Mola; Karel Pavelka; Jacques Sany; Lucas Settas; Joseph Wajdula; Ronald Pedersen; Saeed Fatenejad; Marie Sanda
Journal:  Lancet       Date:  2004-02-28       Impact factor: 79.321

Review 2.  [Balneotherapy and spa therapy of rheumatic diseases in Turkey: a systematic review].

Authors:  M Z Karagülle; M Karagülle
Journal:  Forsch Komplementarmed Klass Naturheilkd       Date:  2004-02

3.  Magnetic resonance imaging of wrist and finger joints in healthy subjects occasionally shows changes resembling erosions and synovitis as seen in rheumatoid arthritis.

Authors:  Bo Ejbjerg; Eva Narvestad; Egill Rostrup; Marcin Szkudlarek; Søren Jacobsen; Henrik S Thomsen; Mikkel Østergaard
Journal:  Arthritis Rheum       Date:  2004-04

4.  Predictive factors in early arthritis: long-term follow-up.

Authors:  H Ralph Schumacher; Wassim Habre; Robert Meador; Elizabeth C Hsia
Journal:  Semin Arthritis Rheum       Date:  2004-02       Impact factor: 5.532

Review 5.  Occupational therapy for rheumatoid arthritis.

Authors:  E M J Steultjens; J Dekker; L M Bouter; D van Schaardenburg; M A H van Kuyk; C H M van den Ende
Journal:  Cochrane Database Syst Rev       Date:  2004

6.  Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial.

Authors:  H A Capell; R Madhok; J A Hunter; D Porter; E Morrison; J Larkin; E A Thomson; R Hampson; F W Poon
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

7.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

Authors:  Edward C Keystone; Arthur F Kavanaugh; John T Sharp; Hyman Tannenbaum; Ye Hua; Leah S Teoh; Steven A Fischkoff; Elliot K Chartash
Journal:  Arthritis Rheum       Date:  2004-05

8.  Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS).

Authors:  Jonathon Dixey; Csilla Solymossy; Adam Young
Journal:  J Rheumatol Suppl       Date:  2004-03

9.  Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs.

Authors:  Harold E Paulus; Daniel Di Primeo; John T Sharp; Harry K Genant; Barbara N Weissman; Michael H Weisman; Marie Sanda
Journal:  J Rheumatol       Date:  2004-03       Impact factor: 4.666

Review 10.  Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis.

Authors:  T Wienecke; P C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2004
View more
  187 in total

Review 1.  Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Clinical guidelines: New guidelines on nondrug treatment in RA.

Authors:  Theodora P M Vliet Vlieland
Journal:  Nat Rev Rheumatol       Date:  2010-05       Impact factor: 20.543

3.  Impact of tight control strategy on rheumatoid arthritis in Sarawak.

Authors:  Cheng Lay Teh; Jin Shyan Wong
Journal:  Clin Rheumatol       Date:  2010-10-01       Impact factor: 2.980

4.  Depression and anxiety associate with less remission after 1 year in rheumatoid arthritis.

Authors:  Aleid C Boer; Tom W J Huizinga; Annette H M van der Helm-van Mil
Journal:  Ann Rheum Dis       Date:  2018-01-08       Impact factor: 19.103

5.  Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Authors:  J S Smolen; E C Keystone; P Emery; F C Breedveld; N Betteridge; G R Burmester; M Dougados; G Ferraccioli; U Jaeger; L Klareskog; T K Kvien; E Martin-Mola; K Pavelka
Journal:  Ann Rheum Dis       Date:  2006-10-26       Impact factor: 19.103

6.  Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?

Authors:  Di Liu; Na Yuan; Guimei Yu; Ge Song; Yan Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 7.  Celecoxib: a review of its use in the management of arthritis and acute pain.

Authors:  James E Frampton; Gillian M Keating
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Priority-setting tools for rheumatology disease referrals: a review of the literature.

Authors:  Carolyn De Coster; Avril Fitzgerald; Monica Cepoiu
Journal:  Clin Rheumatol       Date:  2008-06-17       Impact factor: 2.980

9.  Enhanced MRI in early undifferentiated oligoarthritis of the knee joints: improvements already visible after 2 months of DMARDs treatment.

Authors:  Yasser Emad; Yasser Ragab; Ahmed Shaarawy; Hala Raafat; H A El-Kiki; Johannes J Rasker
Journal:  Clin Rheumatol       Date:  2008-06-18       Impact factor: 2.980

Review 10.  Efficacy of methotrexate in reducing the risk of bone erosion in patients with rheumatoid arthritis: a systematic review of randomized controlled trials.

Authors:  D P Destiani; S Naja; S Dewi; A R Rahmadi; S A S Sulaiman; R Abdulah
Journal:  Osteoporos Int       Date:  2020-11-18       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.